Stroke prevention in non-rheumatic atrial fibrillation

Area of Science:

• Cardiology
• Neurology
• Pharmacology

Background:

• Stroke is a major cause of disability and death.
• Non-rheumatic atrial fibrillation (NRAF) significantly increases stroke risk.
• Anticoagulation therapy is crucial for stroke prevention in NRAF patients.

Purpose of the Study:

• To evaluate the efficacy and safety of warfarin for stroke prevention in NRAF patients.
• To determine the optimal international normalized ratio (INR) target for anticoagulation.
• To identify patient subgroups who benefit most from warfarin therapy.

Main Methods:

• Retrospective analysis of patient data.
• Inclusion of patients with NRAF, with or without prior stroke or transient ischemic attack (TIA).
• Stratification of patients based on age and presence of risk factors.

Main Results:

• Warfarin therapy significantly reduces stroke incidence in NRAF patients.
• Optimal anticoagulation is achieved with an INR between 2.0 and 3.0.
• INR levels below 2.0 offer insufficient protection, while levels above 4.0 increase hemorrhage risk.
• Patients aged 65 or younger without risk factors showed no additional benefit from warfarin compared to aspirin or placebo.
• Older patients and those with risk factors demonstrated significant stroke prevention with recommended warfarin anticoagulation.

Conclusions:

• Warfarin is a highly effective stroke preventative in NRAF patients when therapeutic INR levels are maintained.
• Therapeutic INR range of 2.0-3.0 is essential for optimal efficacy and safety.
• Warfarin is recommended for older NRAF patients and those with risk factors, but not for younger, low-risk individuals.